MEHLMAN CONSULTING, INC. for MAYO CLINIC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Quality payments for providers. Accountable care organizations. Clinical laboratory reimbursement. Physician payment policies. H.R. 2810,the Medicare Patient Access and Quality Improvement Act of 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KELLY RUCKER BINGEL | — |
| DAVID CASTAGNETTI | — |
| ELISE FINLEY PICKERING | — |
| BRUCE MEHLMAN | — |
| STACEY RAMPY | — |
| DEAN ROSEN | — |
| DAVID R THOMAS | — |
| ALLEN L THOMPSON | — |
| ALEX VOGEL | — |
| BRIAN WILD | — |
| CHARLES WOOTERS | — |
| SUSAN ZOOK New | — |
Medical/Disease Research/Clinical Labs MED
NIH appropriations Clinical laboratory reimbursement
| Lobbyist | Covered position, as disclosed |
|---|---|
| KELLY RUCKER BINGEL | — |
| DAVID CASTAGNETTI | — |
| ELISE FINLEY PICKERING | — |
| BRUCE MEHLMAN | — |
| STACEY RAMPY | — |
| DEAN ROSEN | — |
| DAVID R THOMAS | — |
| ALLEN L THOMPSON | — |
| ALEX VOGEL | — |
| BRIAN WILD | — |
| CHARLES WOOTERS | — |
| SUSAN ZOOK New | — |
Health Issues HCR
General health care. General health reform implementation. Health care value and quality. Drug shortage issues. ICD-10 Implementation. H.R. 3204, the Drug Quality and Security Act. S.959, Pharmaceutical Quality, Security, and Accountability Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KELLY RUCKER BINGEL | — |
| DAVID CASTAGNETTI | — |
| ELISE FINLEY PICKERING | — |
| BRUCE MEHLMAN | — |
| STACEY RAMPY | — |
| DEAN ROSEN | — |
| DAVID R THOMAS | — |
| ALLEN L THOMPSON | — |
| ALEX VOGEL | — |
| BRIAN WILD | — |
| CHARLES WOOTERS | — |
| SUSAN ZOOK New | Intern, Rep. Bill Shuster |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.